Edwards Lifesciences Poised for Upward Momentum as CMS TAVR Coverage Decision Nears

Edwards Lifesciences (ticker: EW) finds itself in the spotlight this week as the final national coverage decision (NCD) for its transcatheter aortic valve replacement (TAVR) procedures is expected to be released this month. That key development has captured investor attention amid growing optimism in the structural heart segment.

The company confirmed in its second-quarter earnings released on July 23 that the U.S. Centers for Medicare & Medicaid Services (CMS) will issue a definitive policy on TAVR coverage in September, noting this decision as a major upcoming catalyst for the business. This update was reiterated in multiple market summaries following the earnings report. In that quarter, Edwards reported $1.74 billion in revenue, beating expectations, with adjusted EPS of $0.78 versus consensus of $0.74; notably, TAVR sales reached $1.3 billion. 

Earlier this week, Edwards publicly commented on that pending CMS ruling, signaling its readiness and the potential significance of the policy for accelerating Medicare access to TAVR procedures. Reports emphasized that the inclusion of asymptomatic aortic stenosis patients under Medicare coverage could notably expand the procedure’s addressable market. Analyst coverage reinforced that the CMS outcome is viewed positively.

Within the past seven days, investor filings also showed shifts in institutional ownership: the California State Teachers’ Retirement System increased its holdings, while Amundi trimmed its stake. Several insiders have sold shares, although such movements appear consistent with routine portfolio adjustments rather than signaling a change in outlook.

Meanwhile, EW trades at approximately $85.73 as of September 24, 2026, reflecting a modest pullback in recent weeks. Despite that, multiple analyst reports this month maintained “Buy” or “Moderate Buy” ratings, buoyed by Edwards’ strong second-quarter performance and the impending CMS decision.

Why It Matters

The CMS coverage decision represents more than just policy clarity—it could determine how widely Medicare reimburses TAVR procedures, including for asymptomatic patients with severe aortic stenosis. Approval for broader coverage would likely unlock new patient populations, potentially driving sustained revenue growth in 2027 and beyond.

Investors should monitor the date of the CMS release closely, as well as any details regarding coverage scope. A favorable ruling may serve as a catalyst for upward stock movement, while a more limited decision could temper expectations.

In the meantime, second-quarter earnings remain a solid foundation. Edwards beat consensus on both revenue and EPS, with its structural heart products — especially TAVR and transcatheter mitral and tricuspid therapies — delivering strong growth.

What to Watch Next

• The CMS final coverage determination for TAVR (expected in September)
• Any detail on asymptomatic aortic stenosis inclusion
• Further analyst updates or revisions in light of the CMS decision
• Post-decision stock price reaction and trading volumes

With a clear earnings beat behind it and one of the medtech sector’s most consequential policy decisions imminent, Edwards Lifesciences stands at the cusp of possible upside—pending how CMS shapes access to its core TAVR offering.

Note on stock price: EW closed at $85.73 on September 24, 2026, reflecting a 0.94% decline that day.